Literature DB >> 2840317

Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms.

L E Limbird1.   

Abstract

Many hormones and neurotransmitters attenuate cyclic AMP (cAMP) accumulation in intact cells by virtue of their ability to inhibit adenylate cyclase activity via the GTP-binding protein denoted as Gi. Nonetheless, a number of physiological findings suggest that attenuation of cAMP production is not sufficient to serve as the only signal for eliciting the diverse physiological effects provoked by these various receptor populations. Additional biochemical and electrophysiological changes are known to occur after occupancy of receptors linked to inhibition of adenylate cyclase, including acceleration of Na+/H+ exchange, activation of K+ conductances, and inhibition of voltage-sensitive Ca2+ channels. This review summarizes the current understanding of how these receptors are coupled to their multiple potential effector mechanisms and offers some speculation about the possible interplay between the biochemical and electrophysiological sequels of receptor occupancy. It is hoped that future studies will establish which constellation of possible signaling mechanisms actually brings about changes in metabolic, secretory, or contractile events in different target cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840317     DOI: 10.1096/fasebj.2.11.2840317

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  44 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.

Authors:  P J Pauwels; F C Colpaert
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

3.  The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy.

Authors:  L S Stone; L B MacMillan; K F Kitto; L E Limbird; G L Wilcox
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

4.  Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo.

Authors:  P P Lakhlani; L B MacMillan; T Z Guo; B A McCool; D M Lovinger; M Maze; L E Limbird
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Desipramine selectively potentiates norepinephrine-elicited ERK1/2 activation through the α2A adrenergic receptor.

Authors:  Christopher Cottingham; Adrian Jones; Qin Wang
Journal:  Biochem Biophys Res Commun       Date:  2012-03-03       Impact factor: 3.575

6.  A pervasive mechanism for analgesia: activation of GIRK2 channels.

Authors:  Y A Blednov; M Stoffel; H Alva; R A Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-19       Impact factor: 11.205

7.  Regulation of alpha2AR trafficking and signaling by interacting proteins.

Authors:  Qin Wang; Lee E Limbird
Journal:  Biochem Pharmacol       Date:  2006-12-28       Impact factor: 5.858

8.  Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets.

Authors:  G van Willigen; J W Akkerman
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

9.  Alpha 1-adrenoceptor-mediated inhibition of cellular cAMP accumulation in neonatal rat ventricular myocytes.

Authors:  S Barrett; N Honbo; J S Karliner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-04       Impact factor: 3.000

10.  Multiple G-protein-dependent pathways mediate the antisecretory effects of somatostatin and clonidine in the HT29-19A colonic cell line.

Authors:  G Warhurst; L A Turnberg; N B Higgs; A Tonge; J Grundy; K E Fogg
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.